Sugi Predict

Sugi Predict / Compounds / SCHEMBL6961544

SCHEMBL6961544

SCHEMBL6961544

C[C@@H]1CN(Cc2ccccc2)C[C@H](C)C1O

nearest known ligand 0.68

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ FUCA1 P04066 2/20 0.68
▸ GBA1 P04062 1/20 0.57
▸ MAPT P10636 1/20 0.54
▸ ACHE P22303 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.51
▸ SIGMAR1 Q99720 2/20 0.50
▸ S1PR1 P21453 1/20 0.50
▸ S1PR5 Q9H228 1/20 0.50
▸ MC4R P32245 1/20 0.47
▸ GRIN2B Q13224 2/20 0.47
▸ GRIN1 Q05586 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21462951 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL7226622 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL21462952 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL12427247 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL914849 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL21462424 1.00 FUCA1 (0.68) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL915827 0.91 FUCA1 (0.77) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL6962228 0.91 FUCA1 (0.77) FUCA1GBA1MAPTACHEALDH1A1
SCHEMBL20901984 0.88 FUCA1 (0.60) FUCA1GBA1MAPTACHESIGMAR1
SCHEMBL10041956 0.88 FUCA1 (0.60) FUCA1GBA1MAPTACHESIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729127-A2 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2026-04-22 — — EP disclosed
US-20260042776-A1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2026-02-12 — — US disclosed
US-12486285-B2 BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-02 — — US disclosed
CN-112334475-B BCL6 inhibitors 癌症研究技术有限公司 2024-10-29 — — CN disclosed
CN-117980290-A Cyanopyridine and cyanopyrimidine BCL6 degrading agents 达纳－法伯癌症研究所公司 2024-05-03 — — CN disclosed
CN-117510465-A 5, 6-diphenyl pyrazine-2-piperidine compound and preparation method and application thereof 四川轻化工大学 2024-02-06 — — CN disclosed
US-20230287003-A1 BCL6 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-14 — — US disclosed
EP-4201939-A1 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2023-06-28 — — EP disclosed
EP-3774817-B1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2022-12-07 — — EP disclosed
US-11512095-B2 BCL6 inhibitors THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-11-29 — — US disclosed
US-8183366-B2 Chemokine receptor antagonists NOVARTIS AG (CH) 2012-05-22 — — US disclosed
US-20110015180-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2011-01-20 — — US disclosed
US-20110015180-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2011-01-20 — — US disclosed
US-7858781-B2 Chemokine receptor antagonists NOVARTIS AG (CH) 2010-12-28 — — US disclosed
US-7858781-B2 Chemokine receptor antagonists NOVARTIS AG (CH) 2010-12-28 — — US disclosed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US disclosed
US-20070155721-A1 Chemokine receptor antagonists NOVARTIS AG (CH) 2007-07-05 — — US disclosed
US-6608078-B2 Gramnegative bacteria WOCKHARDT LIMITED (IN) 2003-08-19 — — US disclosed
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment WOCKHARDT RESEARCH CENTER 2002-11-07 — — US disclosed
WO-2001085728-A2 ANTIBACTERIAL CHIRAL 8-(SUBSTITUTED PIPERIDINO)-BENZO [I, J] QUINOLIZINES, PROCESSES, COMPOSITIONS AND METHODS OF TREATMENT WOCKHARDT LIMITED (IN) 2001-11-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015180-A1 Chemokine receptor antagonists ACKR3, CXCR2, CXCR4 FUCA1 2438/4885GBA1 1632/4885MAPT 4746/4885
US-20230287003-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL3 FUCA1 3243/4885GBA1 2013/4885MAPT 3855/4885
US-12486285-B2 BCL6 inhibitors BCL6, BCL6B, BCL3 FUCA1 3243/4885GBA1 2013/4885MAPT 3855/4885
US-20070155721-A1 Chemokine receptor antagonists ACKR3, CXCR2, CXCR4 FUCA1 2460/4885GBA1 1567/4885MAPT 4722/4885
US-11512095-B2 BCL6 inhibitors BCL6, BCL6B, BCL3 FUCA1 3243/4885GBA1 2013/4885MAPT 3855/4885
US-20260042776-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL9 FUCA1 4322/4885GBA1 3455/4885MAPT 3429/4885
US-20020165227-A1 Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment ALPI, POLR1C, POLI FUCA1 1778/4885GBA1 866/4885MAPT 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.